MenQuadfi®
Meningococcal Conjugate Vaccine Against Serogroups A, C, W, Y (Polysaccharide, Conjugated).1
Indications
Primary vaccination and revaccination for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y in individuals aged 6 weeks and older.1
Age of Use
For children from 6 weeks of age, adolescents, adults, and older adults with no upper age limit.1
Vaccination Schedule
- Children 6 weeks to 6 months: Three 0.5 mL doses with an interval of at least 2 months. Revaccination in the second year of life (from 12 months), with a minimum interval of 2 months.
- Children 6 to 12 months: One dose. Revaccination in the second year of life (from 12 months), with a minimum interval of at least 2 months.
- Individuals from 12 months of age and adults: One dose.1
Manufacturing and Registration
- Marketing Authorization Holder: Sanofi Pasteur Inc.1
- Registered in the Russian Federation since 2022.1
- Manufactured at the Nanolek Biomedical Complex since 2024.2
Official Documents
-
1.
Summary of Product Characteristics for MenQuadfi®».
Accessed: 17.07.2025.
-
2.
State Register of Medicines.
Accessed: 17.07.2025.